OPEN LETTER – We stay open for you and your patients – Please read

15. March 2020

We stay open for you and your patients! We used the last days to prepare us to continue our...

Read more

Diagnostic Strategy for Females Suspected of Fabry Disease

18. February 2020

Fabry disease, an X-linked inherited lysosomal storage disorder, can be overlooked in heterozygous females due to random X-inactivation. In...

Read more

Hemoglobinopathies and β-Thalassemia: Investigating High-Res Mass Spectrometry

18. February 2020

Early diagnosis of hemoglobin disorders and Thalassemias are become more important due to a high carrier frequency and ease...

Read more

amedes and ARCHIMEDlife – a new strong international alliance

17. January 2020

ARCHIMEDlife is very proud to announce the strategic alliance with amedes Holding GmbH, a leading provider in interdisciplinary and...

Read more

ARCHIMEDlife and Blueprint Genetics – partnership in North America

25. September 2019

Combining high-quality biochemical testing with innovative genetic testing forms a powerful tool for personalized medicine, clinical research and diagnostics...

Read more

SSIEM 2019 in Rotterdam

27. August 2019

Exciting! Our booth with a brand new look and novel, innovative portfolio of diagnostic tests and services. First time...

Read more

New cut-offs for lysosomal enzyme activities.

6. June 2019

We are happy to inform you that we have introduced a new diagnostic assay for the analysis of lysosomal...

Read more

TDM für Psychopharmaka: (in German)

26. February 2019

Quantitative Bestimmung von Psychopharmaka in Blut, Serum oder Plasma Modernste Analysetechnik mittels Klinischer Massenspektrometrie (exakt, sensitiv, schnell) Kompetente fachärztliche Auskunft...

Read more

Improving our ability to diagnose Hemoglobinopathies.

1. October 2018

Results of a prospective study using High-Resolution Mass Spectrometry. The goal of our study, in cooperation with the University...

Read more

First LEA assay launched

14. March 2018

LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses...

Read more